Connexin Hemichannel Blockers to Preserve Muscle Function After Neuromuscular Injury
Official title: Connexin Hemichannel Blockers to Preserve Muscle Function and Improve Recovery After Neuromuscular Trauma
Funded at Philadelphia VA Medical Center · NIH-11418695 · Data updated 2026-11-12
Aims to protect muscle during severe nerve and muscle injuries by using a small molecule to block channels that contribute to muscle wasting, with hopes of better recovery after surgery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Philadelphia VA Medical Center NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | November 1, 2024 |
| Project end | October 31, 2028 |
| Funding year | 2027 |
| NIH project number | 5I01RX005045-03 |
| Project ID | NIH-11418695 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with severe neuromuscular trauma (e.g., peripheral nerve injury or muscular trauma) who may undergo surgical intervention.
✕Less likely to help
People with conditions not involving acute neuromuscular trauma or those unable to take the study medication may not benefit.
What this research studies
If you’ve had a serious nerve or muscle injury, recovery can stall because muscles waste away while waiting for nerves to reconnect. This project tests boldine, a pill that blocks connexin hemichannels, to see if it can keep muscles from shrinking and help nerves rejoin them sooner. Researchers will study how this works in animal models to understand the underlying biology and measure effects on muscle size, nerve connection, and overall function. The goal is to speed and improve recovery through a pharmacological approach before surgical repair. The work is being done in collaboration across disciplines to translate findings toward patient care.
Why it matters
Potential benefit: If successful, this approach could extend the window for effective surgical repair and improve long-term muscle function after neuromuscular trauma.
How similar studies have gone: Prior studies in preclinical models suggest that blocking connexin hemichannels can mitigate denervation-related damage, but translation to humans is still in early stages.
Where this research is happening
-
Philadelphia VA Medical Center
Philadelphia, United States Active
Researchers
- Principal investigator: Cullen, Daniel Kacy — Philadelphia VA Medical Center
- Study coordinator: Cullen, Daniel Kacy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.